Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.

Minnema, Monique C; Dispenzieri, Angela; Merlini, Giampaolo; Comenzo, Raymond L; Kastritis, Efstathios; Wechalekar, Ashutosh D; Grogan, Martha; Witteles, Ronald; Ruberg, Frederick L; Maurer, Mathew S; Tran, NamPhuong; Qin, Xiang; Vasey, Sandra Y; Weiss, Brendan M; Vermeulen, Jessica; Jaccard, Arnaud

Minnema, Monique C; Dispenzieri, Angela; Merlini, Giampaolo; Comenzo, Raymond L; Kastritis, Efstathios; Wechalekar, Ashutosh D; Grogan, Martha; Witteles, Ronald; Ruberg, Frederick L; Maurer, Mathew S; Tran, NamPhuong; Qin, Xiang; Vasey, Sandra Y; Weiss, Brendan M; Vermeulen, Jessica; Jaccard, Arnaud.

Afiliación

Minnema MC; University Medical Center Utrecht, Utrecht, the Netherlands.
Dispenzieri A; Mayo Clinic, Rochester, Minnesota, USA.
Merlini G; Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Comenzo RL; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Kastritis E; John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, Massachusetts, USA.
Wechalekar AD; National and Kapodistrian University of Athens, Athens, Greece.
Grogan M; University College London, London, United Kingdom.
Witteles R; Mayo Clinic, Rochester, Minnesota, USA.
Ruberg FL; Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California, USA.
Maurer MS; Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA.
Tran N; Columbia University Irving Medical Center, New York, New York, USA.
Qin X; Janssen Research & Development LLC, Los Angeles, California, USA.
Vasey SY; Janssen Research & Development LLC, Spring House, Pennsylvania, USA.
Weiss BM; Janssen Research & Development LLC, Spring House, Pennsylvania, USA.
Vermeulen J; Janssen Research & Development LLC, Spring House, Pennsylvania, USA.
Jaccard A; Janssen Research & Development LLC, Leiden, the Netherlands.

JACC CardioOncol ; 4(4): 474-487, 2022 Nov.

Article en En | MEDLINE | ID: mdl-36444227

Palabras clave

AE, adverse event; AL, amyloid light chain; CR, complete response; D-VCd, daratumumab, bortezomib, cyclophosphamide, and dexamethasone; EFS, event-free survival; FLC, free light chain; Mayo staging system; NT-proBNP, N-terminal probrain natriuretic peptide; NYHA, New York Heart Association; PFS, progression-free survival; SAE, serious adverse event; VCd, bortezomib, cyclophosphamide, and dexamethasone; daratumumab; hs-cTnT, high-sensitivity cardiac troponin T

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: JACC CardioOncol Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google